Precision Medicine

With a novel skin drug launched, Pelthos Therapeutics heads to a key conference. Can its focused strategy convince Wall Street of its blockbuster potential?

ITF Therapeutics will unveil 10 new data presentations on its Duchenne therapy, DUVYZAT, offering critical new insights on long-term safety and efficacy.

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

The Biocodex Microbiota Foundation opens its 10th annual grant, committing a total of half a million dollars to shape the future of U.S. gut health science.

With its newly approved VIZZ eye drop, LENZ Therapeutics is wooing investors, aiming to capture a slice of the massive, underserved presbyopia market.

A landmark FDA approval for Bracco's VUEWAY allows high-quality MRI scans in neonates with half the standard gadolinium dose, easing safety concerns.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

A Swiss firm begins human trials for a non-glucose dialysis solution, aiming to end a 30-year reliance on problematic treatments for kidney patients.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

Travere Therapeutics reports a profitable Q4 driven by its kidney drug FILSPARI, but a revenue miss and a critical FDA decision create a complex outlook.

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

MAIA Pharmaceuticals will bring Teribone™, a proven therapy used in Japan, to the US, aiming to solve the critical patient adherence crisis in osteoporosis care.

A new study reveals a breakthrough hair loss system offers clinically meaningful regrowth for menopausal women in just four months, challenging existing treatments.

A new report reveals a healthcare system at odds with modern life, driving women to skip care. But at-home tech and new information sources are forcing a change.

The spatial biology leader will unveil its roadmap at AGBT 2026, targeting the next frontiers of drug discovery with 3D imaging and human-relevant models.

WellAve Dermatology opens a Mohs surgery center in Easton, bringing a top-tier surgeon and gold-standard cancer care to a medically underserved region.

Clene Inc. faces investors with promising data for ALS and MS, but a looming cash crunch makes its upcoming conference a critical test of survival.

The mobile health firm now reaches 25 states with its tech-driven model, aiming to close care gaps and answer federal critics of in-home assessments.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.